Summary: Takeda’s Zasocitinib (TAK-279) Phase 3 Success

Takeda’s zasocitinib, a next-generation oral TYK2 inhibitor, met all primary and secondary endpoints in two Phase 3 trials for moderate-to-severe plaque psoriasis.

* Results: At week 16, 50%+ of patients achieved clear/almost clear skin (PASI 90), and ~30% reached total clearance (PASI 100).

* Safety: The drug was well-tolerated with no new safety signals, benefiting from a "highly selective" design that avoids typical JAK-inhibitor side effects.

* Timeline: Takeda plans to file for FDA approval in fiscal year 2026.

IBD Perspective: High Stakes for UC & CD

While the psoriasis results are a win, what does it mean for the IBD community? I would suggest "cautious optimism" for two reasons:

* The "Selectivity" Test: Unlike earlier TYK2 drugs (like deucravacitinib) that failed in Ulcerative Colitis (UC), zasocitinib is 1-million-fold more selective for TYK2 than JAK1/2/3. Takeda is betting this extreme precision allows for the higher dosing needed to treat the gut without increasing safety risks.

* Targeting the IL-23 Pathway: TYK2 is a key mediator of the IL-23 pathway, the same pathway targeted by successful IBD biologics like Skyrizi and Tremfya.

These psoriasis results suggest zasocitinib might finally be the "pill version" of these biologics that actually works for IBD.

Current Status: Zasocitinib is currently in Phase 2 trials for both Crohn's disease and Ulcerative Colitis. If the drug can replicate this high level of efficacy in the gut, it would fill a major gap for patients seeking oral alternatives to infusions.